HF
KYMR icon

HRT Financial’s Kymera Therapeutics KYMR Stock Holding History

HRT Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,173
Closed -$1.41M – 4298
2025
Q4 		$1.41M Buy
+18,173
New +$1.23M ﹤0.01% 1518
2025
Q3 		– Sell
-28,906
Closed -$1.26M – 3298
2025
Q2 		$1.26M Buy
+28,906
New +$995K 0.01% 1147
2024
Q4 		– Sell
-45,652
Closed -$2.16M – 2865
2024
Q3 		$2.16M Buy
+45,652
New +$2.02M 0.01% 856
2024
Q1 		– Sell
-107,307
Closed -$2.73M – 2723
2023
Q4 		$2.73M Buy
+107,307
New +$1.92M 0.02% 522
2023
Q3 		– Sell
-73,516
Closed -$1.69M – 2778
2023
Q2 		$1.69M Buy
73,516
+56,725
+338% +$1.63M 0.02% 683
2023
Q1 		$497K Buy
+16,791
New +$542K 0.01% 1393
2022
Q4 		– Sell
-34,943
Closed -$760K – 2834
2022
Q3 		$760K Buy
+34,943
New +$921K 0.01% 1107
2020
Q4 		– Sell
-9,406
Closed -$303K – 2171
2020
Q3 		$303K Buy
+9,406
New +$287K 0.01% 1133

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

HRT Financial's KYMR Position: Q1 2026 in Review

HRT Financial sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 18,173 shares — an estimated $1.41M sold.

HRT Financial first reported a position in KYMR in Q3 2020 and held it in 8 quarters. The position peaked at $2.73M in Q4 2023. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • HRT Financial reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 18,173 Kymera Therapeutics shares in Q1 2026, an estimated $1.41M.
  • HRT Financial first reported a position in Kymera Therapeutics in Q3 2020 and held it in 8 quarters.
  • HRT Financial's Kymera Therapeutics position peaked at $2.73M in Q4 2023.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.